{"id":"etoricoxib-betamethasone-fixed-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Corticosteroid-related effects (insomnia, mood changes)"},{"rate":null,"effect":"Increased infection risk"}]},"_chembl":{"chemblId":"CHEMBL416146","moleculeType":"Small molecule","molecularWeight":"358.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces prostaglandin synthesis, thereby decreasing inflammation and pain. Betamethasone is a corticosteroid that binds glucocorticoid receptors to suppress immune responses and inflammation. The fixed-dose combination leverages both mechanisms for enhanced anti-inflammatory efficacy in inflammatory conditions.","oneSentence":"Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while betamethasone provides additional anti-inflammatory and immunosuppressive effects via glucocorticoid receptor activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:44.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Ankylosing spondylitis"},{"name":"Other inflammatory joint disorders"}]},"trialDetails":[{"nctId":"NCT07454369","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-10-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT07328022","phase":"PHASE3","title":"Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2025-05-14","conditions":"Bursitis, Tendinitis, Synovitis","enrollment":89},{"nctId":"NCT06863701","phase":"PHASE3","title":"Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis","status":"RECRUITING","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2025-01-27","conditions":"Gout Arthritis, Gout Attack","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Etori + Beta"],"phase":"phase_3","status":"active","brandName":"Etoricoxib + Betamethasone fixed dose","genericName":"Etoricoxib + Betamethasone fixed dose","companyName":"Laboratorios Silanes S.A. de C.V.","companyId":"laboratorios-silanes-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while betamethasone provides additional anti-inflammatory and immunosuppressive effects via glucocorticoid receptor activation. Used for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}